Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B

 Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

Shots:

  • Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales
  • The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF) 
  • BBT-877 is an autotaxin inhibitor targeted for the treatment of IPF, currently being evaluated in P-I expected to enter P-II within the next 12 months. In 2017, Bridge in-licensed BBT-877 from LegoChem Biosciences

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post